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Rare diseases are a global public health priority; they
can cause signiﬁcant morbidity and mortality, can gravely
affect quality of life, and can confer a social and economic
burden on families and communities. These conditions are,
by their nature, encountered very infrequently by clinicians.
Thus, clinical practice guidelines are potentially very helpful
in supporting clinical decisions, health policy and resource
allocation. The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system is a
structured and transparent approach to developing and
presenting summaries of evidence, grading its quality, and
then transparently interpreting the available evidence to
make recommendations in health care. GRADE has been
adopted widely. However, its use in creating guidelines for
rare diseases – which are often plagued by a paucity of
high quality evidence – has not yet been explored. RARE-
Bestpractices is a project to create and populate a platform
for sharing best practices for management of rare diseases.
A major aim of this project is to ensure that European
Union countries have the capacity to produce high quality
clinical practice guidelines for rare diseases. On February
12, 2013 at the Istituto Superiore di Sanita, in Rome, Italy,
the RARE-Bestpractices group held the ﬁrst of a series of
2 workshops to discuss methodology for creating clinical
practice guidelines, and explore issues speciﬁc to rare
diseases. This paper summarizes key results of the ﬁrst
workshop, and explores how the current GRADE approach
might (or might not) work for rare diseases. Avenues for
future research are also identiﬁed.
Introduction
The US. National Institutes of Health (NIH) Office of Rare
Diseases Research considers a disease to be rare if it has a preva-
lence of fewer than 200,000 affected individuals in the United
States (for a rate of 1 in 1,500 people), while the European Union
defines rare diseases (RDs) as those affecting less than 1 in 2,000
people.1,2 RDs are frequently life-threatening or seriously debilitat-
ing conditions, which can cause significant morbidity and mortal-
ity, can gravely affect quality of life, and can confer a social and
economic burden on families and communities. They often have
no satisfactory method of treatment.2,3 Many are not the focus of
research interest, market interest or public health policies. There
are thought to be over 7,000 RDs, although the exact number is
not known. Together, they affect over 25 million American citi-
zens and 30 million European Union citizens of all ages. This
underscores the fact that though individual RDs have a low preva-
lence, the total number of patients with RDs is large. For these
reasons, RDs, taken as a whole, are a global public health priority.
In the European Union, special initiatives have been under-
taken to improve research and health services for patients with
RDs. A growing number of national centers of expertise have been
established as a way to provide highly-specialized and complex care
for these patients. However, the centers are named inconsistently;
terms used include “centers of expertise,” “centers of reference,”
“centers of excellence,” and “network of reference.” This heteroge-
neity reflects the divergent practices adopted by Member States for
establishing centers of expertise. Some countries rely on informal
processes, where centers are identified based solely on reputation,
often in the absence of any system to monitor quality of care.
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Other countries have well-established systems and procedures in
place for designating centers of expertise and defining their scope,
as well as providing mechanisms for quality assurance.4 Acknowl-
edgment of the pressing need to share knowledge and resources in
the area of RDs has led to the establishment of European Refer-
ence Networks (ERNs) by several Member States. These are listed,
together with existing centers of expertise, for a range of RDs in
the Orphanet database (http://www.orpha.net). After ten years of
extensive work at the European Union level, a firm basis for the
creation and evaluation of ERNs was provided by Directive 2011/
24/EU on patients’ rights in cross-border healthcare, the Commis-
sion Implementing Decision (2014/287/EU): setting out criteria
for establishing and evaluating European Reference Networks, and
the Commission Delegated Decision 2014/286/EU: setting out
criteria and conditions that European Reference Networks must
fulfil.4-7 The former European Union Committee of Experts on
Rare Diseases (EUCERD), now the Commission Expert Group
on Rare Diseases, contributed significantly to this work (http://ec.
europa.eu/health/rare_diseases/expert_group/index_en.htm).
The International Rare Diseases Research Consortium
(IRDiRC) is a further cooperative effort by the European Com-
mission and the US. National Institutes of Health. IRDiRC is a
network of 40 public and private sector organizations invested in
RD research which aims to accelerate medical breakthroughs for
people affected by RDs. The Consortium has 2 goals to achieve
by 2020, namely to develop the means to diagnose most RDs
and to deliver 200 new therapies for RDs. Clinical research is
also strengthened by the Rare Diseases Clinical Research Net-
work (RDCRN), a network of consortia conducting research in
over 200 RDs.8 A collaborative effort of the US. Office of Rare
Diseases Research (ORDR) and several National Institutes of
Health (NIH) Insitutes/Centers, RDCRN has overseen more
than 120 studies since 2003, enrolling over 24,000 participants.
Data management and coordination is centralized, facilitating
epidemiological and survey research, and data sharing. The estab-
lishment of a patient Contact Registry – an online system to col-
lect contact and diagnosis information volunteered by patients
with RDs – has allowed RDCRN to connect with patients
online, so it can offer more individuals access to research partici-
pation. ORDR also coordinates the Rare Diseases Human Bio-
specimens/Biorepositories (RD-HuB), a searchable database of
biospecimens collected, stored, and distributed by biorepositories
globally.9 (https://biospecimens.ordr.info.nih.gov/) All speci-
mens are linked to the Genetic and Rare Diseases (GARD) Infor-
mation Center, which provides specific educational information
on RDs to patients and health care providers. (http://raredi-
seases.info.nih.gov/gard) Another ORDR project on the horizon
is the NIH/NCATS Global Rare Diseases Patient Registry Data
Repository (GRDR), a web based resource that will securely
aggregate and store de-identified patient information from many
different RD registries.10 (https://grdr.ncats.nih.gov/)
Though global efforts to address the problem of RDs are
underway, clinical decision making for individual patients with
RDs remains complex. Gaining both clinical experience and
good evidence takes significantly more time for these conditions
than for common diseases. Thus, clinical practice guidelines are
potentially very helpful in supporting clinical decision making.
Ideally, clinical practice guidelines summarize existing evidence
for clinical outcomes, and use clear criteria to establish our confi-
dence in effect estimates. In many methodological approaches,
convincing (high quality) evidence often leads to strong treat-
ment recommendations, while unconvincing (low quality) evi-
dence often leads to weaker treatment recommendations.
Systematically created guidelines which use an explicit approach
are invaluable. They allow clinicians to make critical treatment
decisions, and communicate these decisions transparently to
patients and colleagues. Rigorous guidelines also allow policy-
makers to determine whether a given treatment provides value to
stakeholders (so resources can be allocated appropriately), and
can standardize care within and between centers of expertise.
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system helps guideline developers pres-
ent summaries of evidence in a structured way, make transparent
judgements about the quality of evidence, and then systematically
move toward developing recommendations for rigorous clinical
practice guidelines.11 GRADE has been adopted by over 80 organ-
izations worldwide, including WHO.12,13 It has evolved to
encompass not only guideline development for treatments, but
also guideline development for diagnostic tests and strategies.
However, the use of GRADE in creating guidelines for rare dis-
eases has not yet been explored systematically and in detail.
RARE-Bestpractices (http://www.rarebestpractices.eu/) is a
European Seventh Framework Program project that aims to
develop a platform to facilitate information exchange, identifying
and spreading best practices for the management of RDs. One of
its goals is to address the paucity of rigorous clinical practice
guidelines for RDs, and propose methods for guideline creation
and dissemination. The authors of this paper are part of RARE-
Bestpractices, of GRADE and DECIDE (a separate Seventh
Framework Program project that builds on GRADE to develop
new ways of presenting research information in guidelines
(http://www.decide-collaboration.eu)).12,13 On February 12,
2013 at the Istituto Superiore di Sanita, in Rome, Italy, the
RARE-Bestpractices group held the first of a series of 2 work-
shops to discuss methodology for creating clinical practice guide-
lines, and explore issues specific to RDs. This paper summarizes
key results of the first workshop. It reviews facilitators of and bar-
riers to clinical care, research and development of clinical practice
guidelines in RDs. It also discusses how the current GRADE
approach might (or might not) work for these conditions. Ave-
nues for future research are identified as well.
How Are Rare Diseases Different?
The RARE-Bestpractices Guidelines workshop began with an
open forum, where participants discussed perceived characteris-
tics that set rare disorders apart from common diseases. These
characteristics can act as facilitators of or barriers to clinical care,
research and guideline development in RDs (Table 1). These
areas are clearly interrelated (Fig. 1).
An important theme is the general lack of public aware-
ness about RDs. Although these conditions are considered to
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be a global health issue, they are not
an actual priority for policymakers,
funders, and researchers in many coun-
tries. Pharmaceutical companies also
de-emphasize RDs; thought they may
invest significant financial resources in
bringing orphan drugs to the market,
they often struggle to recover costs
through sales of these products.14
Without Orphan Drug Regulations
and cross-sector sponsorship initiatives,
there are few economic incentives for
the pharmaceutical industry to develop
treatments for RDs.15-19 Thus, patients
with RDs generally have limited thera-
peutic options.
Table 1. Facilitators of and barriers to clinical care, research and guideline development in rare diseases (RDs)
Phase Facilitators Barriers
Clinical Care o Though individual RDs have low prevalence, total number of
patients with RDs is large
o Not an actual priority for policymakers, funders
o In some jurisdictions, public funds available to ensure access
to therapy
o Lack of clinical expertise
o Existence of European reference networks, centres of
expertise, and patient associations
o Limited therapeutic options
o Low availability and/or accessibility
o Patient eligibility for treatment, dosing forms and
administration guidelines vary worldwide
o Patients and health care providers may be willing to accept
treatments with greater risk and unclear beneﬁts
Research o Though individual RDs have a low prevalence, total number
of patients with RDs is large
o General lack of public awareness
o In some jurisdictions, public funds available for research o Not an actual priority for funders, researchers
o Existence of European reference networks, centres of
expertise, and patient associations
o Perceived lack of clinical equipoise
o Patients and health care providers may be willing to accept
treatments with greater risk and unclear beneﬁts
o Patients and health care providers may be unwilling to
accept placebo or comparator treatment
o Impossible to calculate relative treatment effects if studies
are single-arm (i.e., do not have a comparator)
o Cannot control study results for baseline effects, as these
are often unknown
o Heterogeneity in studies
o Aggregating data extremely challenging
o Study enrolment difﬁcult
o Many RDs do not have clear diagnostic criteria
o Patients not registered in databases in reliable, harmonised
way
o Dearth of epidemiologists and trialists capable of executing
creative, methodologically sound studies for RDs
Guideline development o In some jurisdictions, public funds available for methodologic
research in guideline creation (e.g. RARE-Bestpractices)
o Paucity of published data on RDs (and much of it is low
quality)
o Increasing uptake of GRADE system to summarize evidence,
grade its quality, and transparently interpret it to make
clinical recommendations
o Often no published evidence at all for critically important
outcomes, or for patient values and preferences
o European Union directive on application of patients’ rights in
cross border healthcare supports European reference
networks, which must have capacity to produce good
practice guidelines
Figure 1. The relationship between clinical care, research and guidelines in rare diseases. Guideline
development process adapted from Qaseem A et al. Ann Intern Med. 2012 Apr 3;156(7):525–31.42
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If agreement is reached that a treatment may have utility in a
RD, accessing treatment can still be prohibitive. Different juris-
dictions have different regulations to help patients with RDs
access treatment. Orphan drugs for RDs often have limited avail-
ability and/or accessibility, conditional approval, and partial or
no funding coverage. Patient eligibility for treatments, dosing
forms and administration guidelines can vary widely from coun-
try to country. This makes aggregating data for research purposes
extremely challenging.
In the face of these limited therapeutic options, patients and
clinicians may have a potentially unreasonable perception or
expectation of benefit. That is, they may feel that any treatment
is better than no treatment – a perception that dismantles the
complex concept of clinical equipoise, and makes it more diffi-
cult to conduct properly controlled clinical trials.20 Patients with
RDs are often well informed, aware of the severity of their condi-
tion and willing to accept greater risk for possible benefit.21
Clinicians may feel compelled to offer potentially harmful or
ineffective treatments, due to a sense of urgency to treat the RD,
as well as pressure from pharmaceutical companies and
patients.22,23 This can create inequity among patients, and
restriction of professional autonomy.
Finally, even if there is a will to rigorously study the
effects of treatments in RDs, performing properly sized, unbi-
ased and unconfounded studies can be difficult. Enrolment of
patients in clinical trials may be hampered by their desire to
receive treatment (making placebo options unacceptable).
Conversely, it may compel patients to pursue enrolment in
very risky trials, so they have a chance at accessing treatment.
Specific study designs, like the parallel RCT-cohort trial,
sequential design, risk based allocation, hierarchical designs,
placebo phase trials, Bayesian designs, and adaptive trials may
be well suited to the study of RDs. They are also increasingly
acceptable to both the US. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA).24-26
However, these types of trials require specific expertise to
design and run. Though pharmaceutical companies and large
institutions are increasingly interested in RDs, there is still a
dearth of epidemiologists and trialists working in this area
who are capable of executing creative, methodologically
sound studies. Indeed, widespread use of innovative trial
design and analysis approaches is limited because trialists,
peer-reviewers, regulatory authorities and other stakeholders
are still unfamiliar with these methods, despite the promise
they show with regard to efficiency gains in RD trials.27
Applying GRADE to rare diseases – the PICO question
GRADE methodology suggests that when framing questions
addressing alternative management strategies in systematic
reviews or guidelines, one must first specify the patient popula-
tion, the intervention, the comparator, and the outcomes of
interest.28 This strategy, commonly known as “PICO” (patient,
intervention, comparator, outcome), ensures that recommenda-
tions are focused and appropriate. When we consider RDs, every
part of the PICO question can pose a challenge, as detailed
below.
Population
Defining the population of interest for any research endeavor”
Also covers: on RDs, including guideline creation, was identified
as a major challenge. Many RDs do not have clear diagnostic cri-
teria. Those that do may be difficult to diagnose, because testing
strategies are inaccessible, risky or costly. This makes it difficult
to identify groups of patients. It might be practical to use broad
definitions of the population in RDs (e.g., incorporate closely
related disease entities) to potentially increase the amount of data
relevant to the PICO question.
Intervention and comparator
GRADE states that PICO questions must define both the
intervention and the comparator. Participants noted that there is
often only one treatment for any given RD, and in many cases,
use of a placebo is not an option due to the severe course of the
untreated disease. Thus, finding studies that use an active or inac-
tive comparator can be difficult. Because patterns of practice can
vary for RDs, treatments are also frequently underused or not
used in a consistent way. It might be practical to use broad defini-
tions of the intervention (e.g., a class of medication) to poten-
tially increase the amount of data relevant to the PICO question.
Outcomes
A key step in creating evidence-based guidelines is determin-
ing critical disease outcomes – factors that are important not just
to providers and health care systems, but also to patients. There
are several challenges in defining relevant outcomes for RDs.
First, outcomes relevant to a specific disease are typically charac-
terized (in terms of severity and patterns of recurrence) in long-
term prospective studies. Such studies are less likely to be avail-
able for RDs, making the selection of relevant outcomes and the
determination of their relative importance challenging. Case
reports and case series are more likely to present a biased view of
any outcomes, as they tend to report unusual and severe events.
Second, relying on surrogate outcomes can be more problematic
in RDs than non-rare diseases; the pathophysiology and empiric
evidence linking them to patient important outcomes are less
likely to be well understood. Third, patient reported outcomes,
such as disease-specific quality of life instruments, are less likely
to be studied and validated in RDs. As a result, the most reliable
outcomes might only be those related to morbidity and mortal-
ity. There are ongoing initiatives focused on outcome develop-
ment. One such initiative is COMET (Core Outcome Measures
in Effectiveness Trials).29-32 (http://www.comet-initiative.org)
COMET is concerned with the development and application of
agreed standardised sets of outcomes, which represent the mini-
mum that should be measured and reported in all clinical trials
of a specific condition. These “core outcome sets” are also suit-
able for use in other study designs.
Applying GRADE to rare diseases – quality of evidence
GRADE requires guideline developers to make an overall rat-
ing of confidence in estimates of effect, based on the quality of
evidence (high, moderate, low, or very low) for each selectedout-
come critical to the patient. The quality of evidence starts as high
e1058463-4 Volume 3 Issue 1Rare Diseases
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for randomized trials, and low for observational studies. GRADE
then assesses 5 factors that decrease confidence in effect estimates:
study limitations; inconsistency of results; indirectness of evi-
dence; imprecision; and publication bias.33 GRADE also assesses
3 factors that increase confidence in effect estimates: large magni-
tude of effect; plausible confounding which would reduce a dem-
onstrated effect; and a dose-response gradient.33 An overall rating
of confidence is based on the ratings of confidence for each criti-
cal outcome. Generally, it is based on the critical outcome that
provides the lowest confidence.34
GRADE’s process to determine confidence in estimates of
effect has value, in that it is formal and transparent. However,
evidence for most critical outcomes in RDs would be rated “very
low,” for a number of reasons. Poor data quality ratings may
make it challenging to provide useful recommendations for end
users of a clinical practice guideline.
Paucity of published data is a serious concern in RDs. Ran-
domized controlled trials and large observational studies (when
they do exist) are frequently plagued by study limitations. Guide-
line developers often have to “settle” for case studies or case series.
Case series may still provide moderate or high quality evidence, if
they report unique outcomes that are highly specific to the condi-
tion of interest. N of 1 trials may also be particularly useful in
non-rapidly progressing chronic RDs, or recurrent, symptomatic
conditions.35 In any case, any systematic review of a RD must
plan to identify observational data, in addition to trial/experi-
mental data.
Studies of RDs may fail to report important outcomes, typi-
cally those for which no effect was observed, or those that capture
important harms. Additionally, they may not be powered to
detect statistically or clinically significant treatment effects.36
Recruitment of patients into studies is difficult, as patients with
RDs are often not registered in databases in a reliable, harmon-
ised way.23,37 If very few patients are affected by a given RD, it
can be difficult to replicate study findings. There is also little clar-
ity on how to incorporate qualitative research into guidelines,
particularly if it is the only type of evidence available for a given
RD. Qualitative studies are not part of GRADE’s quality assess-
ment of effect estimates. However, they can be used for the pro-
cess evaluation of complex interventions, and thus may help
interpret evidence for their effectiveness. They can also be used
to assess patient values and preferences related to the disease, its
outcomes, and interventions of interest.
Indirectness is another common problem in studies of RDs.
Evidence quality decreases when there are differences between
the population, intervention, comparator to the intervention,
and outcome of interest, and those included in the relevant stud-
ies. It is difficult to carry out large studies in well-defined RD
patient populations, so clinicians often use indirect evidence,
extrapolating data from a population that shares some features.
(For example, data from epilepsy – a common disease – is often
used to treat patients with tuberous sclerosis – a rare disease.)
Indirectness can even occur within a defined RD population.
Many RDs have a clear, common genotype. However, the phe-
notype can vary widely. Similar indirectness for interventions,
comparators and outcomes also occurs in RDs. There is often no
evidence on the effect of treatments on critical outcomes in RDs,
and use of surrogate outcomes abound. Multiple comparisons,
where patients have several treatments administered simulta-
neously, are also a challenge in RDs. It can be methodologically
difficult to interpret the resulting data, and separate out the indi-
vidual effects of each treatment on an outcome.
Imprecision is a final area of concern that lowers the quality of
evidence in RDs. When a study includes relatively few patients
who have relatively few events, estimates of effect will have wide
confidence intervals. Studies of RDs often do not even include
precision estimates. When they are available, small patient and
event numbers yield very imprecise estimates of effect. Networks
like RDCRN, which uses an automated patient Contact Registry
to improve patient access to studies, can potentially address the
problem of imprecision, by increasing sample sizes for observa-
tional studies.8 “Meta-registries” like GRDR also hold promise
in aggregating information from far more RD patients than any
one reference center or registry could access. GRDR also offers
opportunities for cross-disease research on RDs that share com-
mon features.10
Applying GRADE to rare diseases – evidence profiles and
summary of findings tables
In the GRADE system, evidence can be summarized in 2
ways: evidence profiles (EPs), and summary of findings (SoF)
tables.38 SoF tables succinctly present aggregate data for each
important outcome, including the absolute risk of the outcome
for the intervention and the comparator, the relative effect of the
intervention, the number of participants and studies considered,
a summary of the quality of evidence, and any other comments
(Table 2). EPs contain similar information, but expand on the
quality of evidence; they include an explicit judgment of each fac-
tor that determines the quality of evidence for each outcome
(Table 3). EPs and SoF tables serve different purposes and are
intended for different audiences. EPs are a detailed record of the
judgments that go into developing a systematic review or guide-
line, and are intended for authors, reviewers and guideline panels.
It is vital for these groups to understand the judgements underly-
ing the overall quality assessments, which are then recorded in
the SoF tables. SoF tables are more concise, and are intended for
a broader audience, including end users of systematic reviews and
guidelines.
EP and SoF tables for a RD may look very different from one
for a common disease. Many studies in RDs have no comparator,
so establishing relative effects is not possible. Treatment of RDs
often considers “baseline effect” (e.g., spontaneous remission) –
this is not traditionally captured in EPs and SOFs. Further, for
some critically important outcomes in RDs, there is no published
evidence at all, yielding “empty” rows.
Applying GRADE to rare diseases– evidence to
recommendation tables
The GRADE system asks guideline creators to consider a
number of factors when making recommendations, including:
the overall quality of the evidence; the balance between benefits
and risks; resource use; and patient values and preferences.39,40
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D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
be
rd
ee
n]
 at
 06
:00
 08
 O
cto
be
r 2
01
5 
Ta
b
le
2.
Sa
m
pl
e
G
RA
D
E
Ev
id
en
ce
Pr
oﬁ
le
fo
ri
nh
al
ed
an
tib
io
tic
s
ve
rs
us
in
tr
av
en
ou
s
an
tib
io
tic
s
fo
rp
ul
m
on
ar
y
ex
ac
er
ba
tio
ns
in
cy
st
ic
ﬁ
br
os
is
4
3
Q
ua
lit
y
as
se
ss
m
en
t
N
o
of
p
at
ie
n
ts
Ef
fe
ct
N
o
of
st
ud
ie
s
D
es
ig
n
R
is
k
of
b
ia
s
In
co
n
si
st
en
cy
In
d
ir
ec
tn
es
s
Im
p
re
ci
si
on
O
th
er
co
n
si
d
er
at
io
n
s
In
h
al
ed
an
ti
b
io
ti
cs
In
tr
av
en
ou
s
an
ti
b
io
ti
cs
R
el
at
iv
e
(9
5%
C
I)
A
b
so
lu
te
Q
ua
lit
y
Im
p
or
ta
n
ce
ad
ve
rs
e
ev
en
ts
-r
en
al
to
xi
ci
ty
2
ra
nd
om
is
ed
tr
ia
ls
se
rio
us
6
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
no
se
rio
us
im
pr
ec
is
io
n
no
ne
24
/2
4
(1
00
%
)
22
/2
2
(1
00
%
)
—
10
00
fe
w
er
pe
r
10
00
(f
ro
m
10
00
fe
w
er
to
10
00
fe
w
er
)
A
A
A
O
M
O
D
ER
A
TE
C
RI
TI
C
A
L
lu
ng
fu
nc
ti
on
-F
EV
11
(m
ea
su
re
d
w
it
h:
lit
re
or
p
er
ce
nt
(%
)p
re
d
ic
te
d
:a
b
so
lu
te
va
lu
es
or
ch
an
g
e
va
lu
es
;B
et
te
r
in
d
ic
at
ed
b
y
lo
w
er
va
lu
es
)
2
ra
nd
om
is
ed
tr
ia
ls
2
se
rio
us
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
no
se
rio
us
im
pr
ec
is
io
n
no
ne
24
22
—
m
ea
n
ra
ng
ed
fr
om
0
to
0
hi
gh
er
A
A
O
O
LO
W
C
RI
TI
C
A
L
ne
ed
fo
r
ho
sp
it
al
ad
m
is
si
on
(f
ol
lo
w
-u
p
14
d
ay
s)
1
ra
nd
om
is
ed
tr
ia
ls
se
rio
us
3
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
se
rio
us
no
ne
2/
16
(1
2.
5%
)
1/
12
(8
.3
%
)
RR
1.
50
(0
.1
5
to
14
.6
8)
42
m
or
e
pe
r
10
00
(f
ro
m
71
fe
w
er
to
10
00
m
or
e)
0%
—
ti
m
e
of
fw
or
k
or
sc
ho
ol
-n
ot
re
p
or
te
d
0
—
—
—
—
—
no
ne
0
—
—
—
IM
PO
RT
A
N
T
q
ua
lit
y
of
lif
e
-n
ot
re
p
or
te
d
0
—
—
—
—
—
no
ne
0
—
—
—
ne
ed
fo
r
ad
d
it
io
na
lI
V
an
ti
b
io
ti
cs
1
ra
nd
om
is
ed
tr
ia
ls
se
rio
us
4
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
se
rio
us
5
no
ne
2/
8
(2
5%
)
0/
10
(0
%
)
RR
6.
11
(0
.3
3
to
11
1.
71
)
—
A
A
O
O
LO
W
IM
PO
RT
A
N
T
0%
—
0%
—
d
ev
el
op
m
en
t
of
re
si
st
an
t
or
g
an
is
m
s
(f
ol
lo
w
-u
p
14
d
ay
s)
1
ra
nd
om
is
ed
tr
ia
ls
2
se
rio
us
7
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
se
rio
us
8
no
ne
9
3/
16
(1
8.
8%
)
1/
12
(8
.3
%
)
RR
2.
25
(0
.2
7
to
19
.0
4)
10
4
m
or
e
pe
r
10
00
(f
ro
m
61
fe
w
er
to
10
00
m
or
e)
A
A
O
O
LO
W
IM
PO
RT
A
N
T
0%
—
ti
m
e
to
ne
xt
p
ul
m
on
ar
y
ex
ac
er
b
at
io
n
1
0
(f
ol
lo
w
-u
p
2
w
ee
ks
;B
et
te
r
in
d
ic
at
ed
b
y
lo
w
er
va
lu
es
)
1
ra
nd
om
is
ed
tr
ia
ls
se
rio
us
1
1
no
se
rio
us
in
co
ns
is
te
nc
y
no
se
rio
us
in
di
re
ct
ne
ss
no
se
rio
us
im
pr
ec
is
io
n
no
ne
0
—
—
M
D
0
hi
gh
er
(0
to
0
hi
gh
er
)1
2
A
A
A
O
M
O
D
ER
A
TE
IM
PO
RT
A
N
T
1
th
er
e
w
as
in
su
fﬁ
ci
en
ti
nf
or
m
at
io
n
fo
rm
et
a-
an
al
ys
is
:o
ne
st
ud
y
(C
oo
pe
r)
lis
te
d
Be
fo
re
an
d
A
ft
er
:I
nt
er
ve
nt
io
n
B:
42
%
,A
:5
5%
C
on
tr
ol
:B
:3
9%
,A
:5
2%
on
e
st
ud
y
(S
te
ph
en
s)
lis
te
d
ch
an
ge
in
FE
V1
:I
nt
er
ve
nt
io
n:
6.
7%
,C
on
tr
ol
:3
.9
%
->
bo
th
re
po
rt
ed
no
si
gn
iﬁ
ca
nt
di
ff
er
en
ce
.
2
2
st
ud
ie
s
re
po
rt
ed
on
th
is
ou
tc
om
e:
on
e
re
po
rt
ed
RR
an
d
on
e
on
ly
st
at
ed
th
at
in
th
e
in
ha
le
d
gr
ou
p,
3
ou
to
f3
9
st
ra
in
s
w
er
e
re
si
st
an
t,
in
th
e
IV
gr
ou
p
4
re
si
st
an
ce
s
(n
ot
lis
te
d
in
th
is
ev
id
en
ce
pr
oﬁ
le
).
3
un
cl
ea
rr
is
k
of
ra
nd
om
se
qu
en
ce
ge
ne
ra
tio
n,
al
lo
ca
tio
n
co
nc
ea
lm
en
t,
no
bl
in
di
ng
,u
nc
le
ar
ris
k
of
in
co
m
pl
et
e
ou
tc
om
e
da
ta
.
4
un
cl
ea
rr
is
k
of
ra
nd
om
se
qu
en
ce
ge
ne
ra
tio
n,
un
cl
ea
rr
is
k
of
al
lo
ca
tio
n
co
nc
ea
lm
en
t,
no
bl
in
di
ng
et
c.
5
ve
ry
w
id
e
C
I.
6
no
bl
in
di
ng
et
c.
7
no
bl
in
di
ng
et
c.
(s
ee
pr
ev
io
us
fo
ot
no
te
s)
.
8
ve
ry
w
id
e
C
I
9
ou
tc
om
e
w
as
st
at
ed
to
be
m
ea
su
re
d
in
3
tr
ia
ls
bu
tr
ep
or
te
d
in
on
ly
2
tr
ia
ls
.
1
0
si
ng
le
st
ud
y
in
ab
st
ra
ct
fo
rm
.
1
1
un
cl
ea
r
ris
k
of
ra
nd
om
se
qu
en
ce
ge
ne
ra
tio
n,
un
cl
ea
rr
is
k
of
al
lo
ca
tio
n
co
nc
ea
lm
en
t,
no
bl
in
di
ng
.
1
2
no
nu
m
be
rs
gi
ve
n:
tim
e
to
ne
xt
ex
ac
er
ba
tio
n
m
ax
im
al
in
th
e
on
ce
-d
ai
ly
in
ha
le
d
an
tib
io
tic
gr
ou
p,
le
ss
in
th
e
tw
ic
e
da
ily
IV
an
tib
io
tic
gr
ou
p,
sh
or
te
st
tim
e:
gr
ou
p
re
ce
iv
in
g
IV
an
tib
io
tic
s
th
re
e-
tim
es
da
ily
.
e1058463-6 Volume 3 Issue 1Rare Diseases
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
be
rd
ee
n]
 at
 06
:00
 08
 O
cto
be
r 2
01
5 
Ta
b
le
3.
Sa
m
pl
e
G
RA
D
E
Su
m
m
ar
y
of
Fi
nd
in
gs
Ta
bl
e
fo
ro
ra
lo
se
lta
m
iv
ir
ve
rs
us
no
an
tiv
ira
lt
he
ra
py
in
in
ﬂ
ue
nz
a4
4
Su
m
m
ar
y
of
Fi
n
d
in
g
s
Q
ua
lit
y
as
se
ss
m
en
t
St
ud
y
ev
en
t
ra
te
s
(%
)
A
n
ti
ci
p
at
ed
ab
so
lu
te
ef
fe
ct
s
Fo
llo
w
up
Pa
rt
ic
ip
an
ts
(s
tu
d
ie
s)
O
ve
ra
ll
q
ua
lit
y
of
ev
id
en
ce
W
it
h
n
o
an
ti
vi
ra
l
tr
ea
tm
en
t
W
it
h
os
el
ta
m
iv
ir
R
el
at
iv
e
ef
fe
ct
(9
5%
C
I)
R
is
k
w
it
h
n
o
an
ti
vi
ra
l
tr
ea
tm
en
t
A
b
so
lu
te
ef
fe
ct
w
it
h
O
se
lt
am
iv
ir
(9
5%
C
I)
M
or
ta
lit
y
68
1
(3
st
ud
ie
s)

OO
LO
W
1
59
/2
42
(2
4.
4%
)
31
/4
39
(7
.1
%
)
A
dj
us
te
d
O
R
0.
23
(0
.1
3
to
0.
43
)
24
0
de
at
hs
pe
r
10
00
17
2
fe
w
er
de
at
hs
pe
r
10
00
(f
ro
m
12
0
to
20
1
fe
w
er
)
H
os
pi
ta
lis
at
io
n
15
07
10
(4
st
ud
ie
s)

OO
LO
W
4
12
38
/
10
05
85
(1
.2
%
)
43
1/
50
12
5
(0
.8
6%
)
A
dj
us
te
d
O
R
0.
75
(0
.6
6
to
0.
89
)
12
ho
sp
ita
lis
at
io
ns
pe
r
10
00
3
fe
w
er
ho
sp
ita
lis
at
io
ns
pe
r
10
00
(f
ro
m
1
to
4
fe
w
er
)
IC
U
ad
m
is
si
on
s/
m
ec
ha
ni
ca
lv
en
ti
la
ti
on
/r
es
p
ir
at
or
y
fa
ilu
re
10
32
(6
st
ud
ie
s5
)
O
OO
VE
RY
LO
W
1
,6
du
e
to
ris
k
of
bi
as
,
in
co
ns
is
te
nc
y
—
20
0/
10
32
(1
9.
4%
)P
oo
le
d
Ri
sk
13
.0
%
(9
5%
C
I1
1
to
15
%
)
—
—
D
ur
at
io
n
of
ho
sp
it
al
is
at
io
n
(d
ay
s)
83
2
(5
st
ud
ie
s)
O
OO
VE
RY
LO
W
1
,5
,6
du
e
to
ris
k
of
bi
as
,
in
co
ns
is
te
nc
y
—
83
2
—
—
Th
e
m
ea
n
du
ra
tio
n
of
ho
sp
ita
ls
ta
y
w
as
5.
16
da
ys
(5
.0
2
to
5.
29
)
D
ur
at
io
n
of
si
g
ns
an
d
sy
m
p
to
m
s
(m
ea
su
re
d
fr
om
on
se
t
of
sy
m
p
to
m
s
or
tr
ea
tm
en
t)
(t
im
e
to
re
tu
rn
to
no
rm
al
ac
ti
vi
ty
w
as
no
t
m
ea
su
re
d
)
58
42
(6
st
ud
ie
s)
O
OO
VE
RY
LO
W
1
,6
du
e
to
in
co
ns
is
te
nc
y
44
9
53
93
—
—
Th
e
m
ea
n
tim
e
w
as
0.
91
st
an
da
rd
de
vi
at
io
ns
lo
w
er
(1
.2
5
to
0.
57
lo
w
er
)7
C
om
p
lic
at
io
ns
-P
ne
um
on
ia
15
04
66
(3
st
ud
ie
s)
O
OO
VE
RY
LO
W
4
,6
du
e
to
in
co
ns
is
te
nc
y
21
11
/
10
04
49
(2
.1
%
)
64
7/
50
01
7
(1
.3
%
)
A
dj
us
te
d
O
R
0.
83
(0
.5
9
to
1.
16
)
21
pn
eu
m
on
ia
s
pe
r
10
00
4
fe
w
er
pn
eu
m
on
ia
s
pe
r
10
00
(f
ro
m
9
fe
w
er
to
3
m
or
e)
C
ri
ti
ca
lA
d
ve
rs
e
Ev
en
ts
10
49
30
(5
st
ud
ie
s)

OO
LO
W
4
60
81
7
44
11
3
Ra
te
Ra
tio
0.
76
(0
.7
to
0.
81
)
42
0
ad
ve
rs
e
ev
en
ts
pe
r
10
00
pa
tie
nt
ye
ar
s
10
1
fe
w
er
ad
ve
rs
e
ev
en
ts
pe
r
10
00
pa
tie
nt
ye
ar
s
(f
ro
m
80
to
12
6
fe
w
er
)
1
A
lth
ou
gh
w
e
di
d
no
t
do
w
ng
ra
de
,p
ub
lic
at
io
n
bi
as
ca
nn
ot
be
ex
cl
ud
ed
.;
2
St
ud
ie
s
no
ta
dj
us
te
d
fo
rp
ot
en
tia
lc
on
fo
un
di
ng
fa
ct
or
s.
;3
Si
gn
iﬁ
ca
nt
di
ff
er
en
ce
s
in
ef
fe
ct
fo
rp
an
de
m
ic
ve
rs
us
se
as
on
al
in
ﬂ
ue
nz
a
(s
ee
su
bg
ro
up
an
al
ys
es
ta
bl
e)
.;
4
Pu
bl
ic
at
io
n
bi
as
a
co
nc
er
n
si
nc
e
la
rg
e
st
ud
ie
s
ha
d
fo
r-
pr
oﬁ
t
fu
nd
in
g
an
d
w
ei
gh
te
d
he
av
ily
in
an
al
ys
es
.;
5
N
o
in
de
pe
nd
en
tc
om
pa
ris
on
gr
ou
p.
;6
H
ig
h
he
te
ro
ge
ne
ity
am
on
g
st
ud
ie
s.
;7
Th
is
tr
an
sl
at
es
to
re
du
ce
d
sy
m
pt
om
du
ra
tio
n
of
ap
pr
ox
im
at
el
y
33
ho
ur
s
(9
5%
C
I2
1
to
45
ho
ur
s)
.D
es
pi
te
th
e
la
rg
e
ef
fe
ct
w
e
di
d
no
t
up
gr
ad
e
be
ca
us
e
th
er
e
w
as
im
po
rt
an
t
in
co
ns
is
te
nc
y
ac
ro
ss
st
ud
ie
s.
www.tandfonline.com e1058463-7Rare Diseases
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
be
rd
ee
n]
 at
 06
:00
 08
 O
cto
be
r 2
01
5 
GRADE formalizes the evaluation of these factors using the Evi-
dence to Recommendation (EtR) framework.41 It can be chal-
lenging to move from evidence to recommendations, in light of
the lack of high quality evidence for RDs. End users may not
find a guideline useful if it summarizes evidence, but ultimately
cannot make recommendations for or against any treatment. For
RDs, where a bedrock of high quality evidence is not always
available, it is important that guideline panels not resort to mak-
ing no recommendation at all; a more pragmatic approach is to
provide some guidance to end users, even if it is in the form of
weak recommendations. Uncertainty about an intervention’s
benefit in a given RD may also be a valid reason for a panel to
recommend against it, particularly if there is more compelling
evidence of harm. Useful recommendations can also be made for
RDs when considering treatment of symptoms (e.g., pain). The
needed evidence for these recommendations may be derived
from studies of symptomatic treatment in the setting of compara-
ble non-rare diseases. Useful recommendations can similarly be
made for complications of RDs that are themselves non-rare
(e.g., chronic kidney disease, congestive heart failure); moderate
or high quality evidence likely exists for these complications. RD
guideline panels can also opt to make “recommendations for
research” – recommendations to only use treatments as part of an
evaluative process which collects information about benefits,
adverse events, and patient values and preferences. This not only
provides end users with helpful guidance, it encourages them to
add to the body of knowledge. The need for published research
on patient values and preferences, partnerships with patient
groups, and representation of patients on guideline panels –
shortcomings in both rare and non-rare disease – should also be
identified.
Conclusions
Rigorous clinical practice guidelines are needed to improve
the care of the millions of people worldwide who suffer from
RDs, and fuel the work of Reference Networks and Centers of
Expertise. The first RARE-Bestpractices Workshop identified key
features that set RDs apart from common diseases, and make
them more challenging to study in a rigorous way. We must keep
these features in mind as we create methodology suitable to
develop and update best practice guidelines in RDs. The applica-
tion of a RD perspective may be relevant to genomic/genetic test-
ing and, ultimately, may be applicable to the entire field of
“personalized medicine.”
Members of GRADE and RARE-Bestpractices will continue
to work together to further test and adapt the GRADE system
for the creation of guidelines for RDs. The goal is to formalize a
systematic process that can be used to create evidence-based prac-
tice guidelines that are useful to patients, clinicians, researchers,
industry, and policy makers in the RD community.
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